Adjunctive Sedation With Dexmedetomidine for the Prevention of Severe Inflammation and Septic Encephalopathy

Sepsis-Associated Encephalopathy Clinical Trial

— ADVISE  

Official title:

Adjunctive Sedation With Dexmedetomidine for the Prevention of Severe Inflammation and Septic Encephalopathy: a Pilot Randomized Controlled Study.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04076826
• Other study ID #: 4051
• Status: Completed
• Phase: N/A
• Start date: September 1, 2019
• Est. completion date: July 8, 2022

Study information

• Verified date: February 2023
• Source: University Hospital Inselspital, Berne
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Septic encephalopathy (SE) is defined as acute cerebral dysfunction in patients with sepsis or septic shock. SE occurs in up to 50% of critically ill patients with sepsis and is associated with a high mortality and morbidity. The pathophysiology of SE is complex and involves increased levels of inflammatory mediators such as tumor necrosis factor (TNF)-α, Interleukin (IL)-1 and IL-6, leading to blood brain barrier dysfunction and neuronal inflammation. Several biomarkers of neuronal injury have been proposed to identify patients with SE. Of these biomarkers, S100-β has the highest sensitivity and specificity.

Sedation with Dexmedetomidine (DEX) is a promising strategy for the management of these patients, as DEX has been shown to decrease the production of inflammatory mediators in experimental models of sepsis. In clinical studies, DEX lowers the incidence of delirium and critical illness polyneuropathy. However, its effectiveness in treatment and prevention of SE remains unclear.

The aim of the present study is to investigate the effect of two standard sedation protocols (Dexmedetomidine sedation vs. Propofol / Midazolam) on serum markers of SE in critically ill patients with sepsis who require sedation and mechanical ventilation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: July 8, 2022
• Est. primary completion date: June 17, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• The participant is aged 18 years or older

• The participant has been intubated and is receiving mechanical ventilation

• The participant requires sedative medication for comfort, safety or to facilitate the delivery of life support measures

• The participant has either a central venous or an arterial catheter inserted within 24 hours of admission

• The participant has a diagnosis of sepsis based on the recent SEPSIS-3 consensus clinical criteria.

Exclusion Criteria:

• Age < 18 years

• The treating physician believes that the participant will remain intubated for <24 hours or the participant has been intubated for diagnostic or therapeutic procedures as the sole reason for mechanical ventilation.

• Participants with any of the following admission diagnosis: acute cerebral vascular event, traumatic brain injury, epilepsy, hypoxic brain injury, meningitis, encephalitis

• Participants with history of melanoma (S 100-ß is elevated in melanoma participants)

• Participants with schizophrenia or other chronic psychiatric conditions

• Admission for drug overdose

• Planned administration of ongoing neuromuscular blockade

• Heart rate < 55 / min or an atrioventricular block > grade 2a in the absence of a functioning pacemaker

• Known hypersensitivity or allergy to any of the sedative medications used in this study.

• DNR (do not resuscitate) or DNI (do not intubate) orders

• Death is deemed to be imminent or inevitable during this admission and either the attending physician, participant or substitute decision maker is not committed to active treatment

• Women who are pregnant or breast feeding

• Known or suspected non-compliance, drug or severe alcohol abuse

• Inability of the participant to understand the procedures of the study, e.g. due to language problems, psychological disorders, or dementia

• Previous enrolment into the current study

• Enrolment of the investigator, his/her family members, employees and other dependent persons

Related Conditions & MeSH terms

• Brain Diseases
• Inflammation
• Sepsis-Associated Encephalopathy

Intervention

Drug:
• Dexmedetomidine
Dexmedetomidine infusion will be commenced in accordance with the hospital's local sedation protocol, without a loading dose, at a rate of 0.1 - 1.4 mcg/kg/hour to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician. Infusion will be continued until sedation is no longer clinically indicated up to a maximum of 7 days after enrolment.
• Propofol or Midazolam
Propofol and/or Midazolam will be used according to Hospital guidelines to maintain sedation as per Richmond Agitation-Sedation Scale (RASS) sedation range specified by the treating clinician.

Diagnostic Test:
• Blood sampling
In all participants, we will collect blood samples for measurement of neuronal and systemic biomarkers of inflammation at randomization (baseline), at day 1, day 2 and day 3 after randomization.

Locations

Country	Name	City	State
Switzerland	Inselspital, Bern University Hospital	Bern

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Inselspital, Berne

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	S100-ß	Serum concentration of S100-ß	at 48 hours after randomization
Secondary	Neuron-specific enolase	Serum concentration of Neuron-specific enolase	first 3 days after randomization
Secondary	Interleukin 1-beta	Serum concentration of Interleukin 1-beta	first 3 days after randomization
Secondary	Interleukin 6	Serum concentration of Interleukin 6	first 3 days after randomization
Secondary	TNF alpha	Serum concentration of TNF alpha	first 3 days after randomization
Secondary	Acetylcholinesterase activity	Acetylcholinesterase activity will be measured using a point-of-care device and reported as Units/grams Haemoglobin	first 3 days after randomization
Secondary	Butyrylcholinesterase activity	Butyrylcholinesterase activity will be measured using a point-of-care device and reported as Units/L	first 3 days after randomization